Literature DB >> 7400685

Studies on plasma lipoproteins during absorption of exogenous lecithin in man.

F U Beil, S M Grundy.   

Abstract

Human subjects were infused intraduodenally with either lecithin (150 mg/kg/hr) or safflower oil (100 mg/kg/hr)of similar fatty acid composition, and plasma lipoproteins were studied when constant plasma lipid levels were reached. Both types of fat induced increases of lipoproteins of Sf > 400 (chylomicrons) and Sf 20--400 (VLDL). Lecithin infusions produced increases predominantly in VLDL, whereas infusion of safflower oil induced mainly chylomicrons. Chylomicrons derived from lecithin were generally smaller and had a high phospholipid:triglyceride ratio (mean 0.15) than those produced during safflower oil infusions (mean 0.08). The increases in VLDL from both lipids occurred mainly in larger particles of this density range. This "incremental VLDL" had a lower cholesterol:triglyceride ratio (0.098) than preinfusion VLDL (0.283) and probably represented "small chylomicrons" of gut origin. The differences in lipoproteins resulting from infusion of lecithin and safflower oil in human subjects were not observed in rats; in the latter, lecithin induced large chylomicrons to the same extent as did safflower oil. Lecithin absorption measured over 50- or 100-cm intestinal segments averaged 41%, but was probably greater over the whole of the small intestine. Lecithin infusion unexpectedly was found to decrease markedly the absorption of cholesterol in the upper part of the small intestine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7400685

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  23 in total

Review 1.  Intestinal phospholipid and lysophospholipid metabolism in cardiometabolic disease.

Authors:  David Y Hui
Journal:  Curr Opin Lipidol       Date:  2016-10       Impact factor: 4.776

2.  Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults.

Authors:  Amalia Diakidou; Maria Vertzoni; Konstantinos Goumas; Erik Söderlind; Bertil Abrahamsson; Jennifer Dressman; Christos Reppas
Journal:  Pharm Res       Date:  2009-07-02       Impact factor: 4.200

3.  Pancreatic lipase/colipase-mediated triacylglycerol hydrolysis is required for cholesterol transport from lipid emulsions to intestinal cells.

Authors:  S C Young; D Y Hui
Journal:  Biochem J       Date:  1999-05-01       Impact factor: 3.857

4.  Bile increases intestinal lymphatic drug transport in the fasted rat.

Authors:  Natalie L Trevaskis; Christopher J H Porter; William N Charman
Journal:  Pharm Res       Date:  2005-08-16       Impact factor: 4.200

5.  Group 1B phospholipase A2-mediated lysophospholipid absorption directly contributes to postprandial hyperglycemia.

Authors:  Eric D Labonté; R Jason Kirby; Nicholas M Schildmeyer; April M Cannon; Kevin W Huggins; David Y Hui
Journal:  Diabetes       Date:  2006-04       Impact factor: 9.461

6.  [Decrease of serum lipoproteins and increase in apolipoproteins A-I and A-II following oral administration of multiple unsaturated phospholipids. Observations on the effect of nutrition on the results].

Authors:  W Spann; G Wolfram; N Zöllner
Journal:  Klin Wochenschr       Date:  1987-07-01

Review 7.  Revisiting Human Cholesterol Synthesis and Absorption: The Reciprocity Paradigm and its Key Regulators.

Authors:  Peter A S Alphonse; Peter J H Jones
Journal:  Lipids       Date:  2015-11-30       Impact factor: 1.880

8.  Hyperlipoproteinaemia and atherosclerosis in rabbits fed low-level cholesterol and lecithin.

Authors:  C E Hunt; L A Duncan
Journal:  Br J Exp Pathol       Date:  1985-02

9.  Influence of dietary soybean and egg lecithins on lipid responses in cholesterol-fed guinea pigs.

Authors:  B C O'Brien; S M Corrigan
Journal:  Lipids       Date:  1988-07       Impact factor: 1.880

10.  Influence of dietary egg and soybean phospholipids and triacylglycerols on human serum lipoproteins.

Authors:  B C O'Brien; V G Andrews
Journal:  Lipids       Date:  1993-01       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.